American Heart Journal
Volume 141, Issue 2 , Pages 301-305 , February 2001

Statistical approaches and policies for the operations of Data and Safety Monitoring Committees

References 

  1. DeMets DL, Pocock SJ, Julian DG. The agonising negative trend in monitoring of clinical trials. Lancet. 1999;354:1983–1988
  2. Coronary Drug Project Research Group . Practical aspects of decision making in clinical trials: the coronary drug project as a case study. Controlled Clin Trials. 1981;1:363–376
  3. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. E-10, Choice of control group in clinical trials. Finalized Guideline available at http://www.pharmweb.net/pwmirror/pw9/ifpma/ich1.htmlJuly 2000.;
  4. Jones B, Jarvis P, Lewis JA, et al.  Trials to assess equivalence: the importance of rigorous methods. BMJ. 1996;313:36–39
  5. Temple R. Problems in interpreting active control equivalence trials. Accountability Res. 1996;4:267–275
  6. Temple R, Ellenberg SS. Placebo-controlled trials and active control trials in the evaluation of new treatments, 1: ethical and scientific issues. Ann Intern Med. 2000;133:455–463
  7. Freedman LS, Spiegelhalter DJ, Parmar MK. The what, why and how of Bayesian clinical trials monitoring. Stat Med. 1994;13:1371–1383
  8. Packer M, Carver JR, Rodeheffer RJ, et al.  Effect of oral milrinone on mortality in severe chronic heart failure: the PROMISE Study Research Group. N Engl J Med. 1991;325:1468–1475
  9. Packer M, Rouleau J, Swedberg K, et al.  PROFILE Investigators, effect of flosequinone on survival in chronic heart failure: preliminary results of the PROFILE study [abstract]. Circulation. 1993;301(1 suppl):I405
  10. Hampton JR, van Veldhuisen DJ, Kleber FX, et al.  Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure: Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators. Lancet. 1997;349:971–977
  11. Swedberg K, Held P, Kjekshus J, et al.  Effect of the early administration of enalapril on mortality in patients with acute myocardial infarction: results of the Cooperative New Scandinavian Enalapril Survival Study II (Consensus II). N Engl J Med. 1992;327:678–684
  12. Fisher B, Dignam J, Wolmark N, et al.  Tamoxifen and chemotherapy for lymph node–negative, estrogen receptor–positive breast cancer. J Natl Cancer Inst. 1997;89:1673–1682
  13. Dignam JJ, Bryant J, Wieand HS, et al.  Early stopping of a clinical trial when there is evidence of no treatment benefit: protocol B-14 of the National Surgical Adjuvant Breast and Bowel Project. Controlled Clin Trials. 1998;19:575–588
  14. Berger PB, Ellis SG, Holmes DR, et al.  Relationship between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute myocardial infarction: results from the Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes (GUSTO-IIb) trial. Circulation. 1999;100:14–20
  15. Antman EM. Hirudin in acute myocardial infarction: Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. Circulation. 1996;94:911–921
  16. Saravolatz LD, Winslow DL, Collins G, et al.  Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter: investigators for the Terry Beirn Community Programs for Clinical Research on AIDS. N Engl J Med. 1996;335:1099–1106
  17. Dixon DO, Lagakos SW. Should data and safety monitoring boards share confidential interim data?. Controlled Clin Trials. 2000;21:1–6
  18. Fleming TR, Ellenberg S, DeMets DL. Monitoring clinical trials: issues and controversies regarding confidentiality. Stat Med. In press.
  19. SYMPHONY Investigators . Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial. Lancet. 2000;355:337–345
  20. Cannon CP, McCabe CH, Wilcox RG, et al.  Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. Circulation. 2000;102:149–156
  21. O’Neill WW, Serruys P, Knudtson M, et al.  Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization: EXCITE Trial Investigators. Evaluation of Oral Xemilofiban in Controlling Thrombotic Events. N Engl J Med. 2000;342:1316–1324
  22. Pocock SJ. When to stop a clinical trial. BMJ. 1992;305:235–240
  23. Peto R, Pike MC, Armitage P, et al.  Design and analysis of randomized clinical trials requiring prolonged observations of each patient, I: introduction and design. Br J Cancer. 1976;34:585–612

☆ Reprints not available from the authors.

☆☆ Am Heart J 2000;141:301-5.

PII: S0002-8703(01)62607-3

doi: 10.1067/mhj.2001.113152

American Heart Journal
Volume 141, Issue 2 , Pages 301-305 , February 2001

Article Tools